*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?
Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month 9 if the PSA level was greater than 1.0 ng/mL. ADT was resumed when PSA increased to greater than or equal to 5.0 ng/mL. The trial end points included calculating the time the men were off treatment, their PSA nadir after 9 months of IADT, [...]